Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

Lisa J. Christopher, Donghui Cui, Chiyuan Wu, Roger Luo, James A. Manning, Samuel J. Bonacorsi, Michael Lago, Alban Allentoff, Francis Y. F. Lee, Betty McCann, Susan Galbraith, Donald P. Reitberg, Kan He, Anthony Barros, Anne Blackwood-Chirchir, W. Griffith Humphreys and Ramaswamy A. Iyer
Drug Metabolism and Disposition July 2008, 36 (7) 1357-1364; DOI: https://doi.org/10.1124/dmd.107.018267
Lisa J. Christopher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donghui Cui
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chiyuan Wu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Luo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James A. Manning
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel J. Bonacorsi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Lago
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alban Allentoff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francis Y. F. Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Betty McCann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Galbraith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald P. Reitberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kan He
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Barros
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Blackwood-Chirchir
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Griffith Humphreys
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramaswamy A. Iyer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

SPRYCEL (dasatinib, BMS-354825; Bristol-Myers Squibb, Princeton, NJ), a multiple kinase inhibitor, is currently approved to treat chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia tumors in patients who are resistant or intolerant to imatinib mesylate (Gleevec; Novartis, Basel, Switzerland). After a 100-mg single p.o. dose of [14C]dasatinib to healthy volunteers, the radioactivity was rapidly absorbed (Tmax ∼0.5 h). Both dasatinib and total radioactivity (TRA) plasma concentrations decreased rapidly with elimination half-life values of <4 h. Dasatinib was the major drug-related component in human plasma. At 2 h, dasatinib accounted for 25% of the TRA in plasma, suggesting that metabolites contributed significantly to the total drug-related component. There were many circulating metabolites detected that included hydroxylated metabolites (M20 and M24), an N-dealkylated metabolite (M4), an N-oxide (M5), an acid metabolite (M6), glucuronide conjugates (M8a,b), and products of further metabolism of these primary metabolites. Most of the administered radioactivity was eliminated in the feces (85%). Urine recovery accounted for <4% of the dose. Dasatinib accounted for <1 and 19% of the dose in urine and feces, respectively, suggesting that dasatinib was well absorbed after p.o. administration and extensively metabolized before being eliminated from the body. The exposures of pharmacologically active metabolites M4, M5, M6, M20, and M24 in patients, along with their cell-based IC50 for Src and Bcr-Abl kinase inhibition, suggested that these metabolites were not expected to contribute significantly toward in vivo activity.

Footnotes

  • Part of this work has been presented previously at the 2006 International Society for the Study of Xenobiotics meeting, 2005 American Association of Pharmaceutical Scientists meeting, and 2007 American Association for Cancer Research meeting.

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

  • doi:10.1124/dmd.107.018267.

  • ABBREVIATIONS: dasatinib, BMS-354825, [N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-thiazole-5-carboxamide]; CML, chronic myelogenous leukemia; ADME, absorption, distribution, metabolism, and excretion; HPLC, high-performance liquid chromatography; TRA, total radioactivity; LC/MS/MS, liquid chromatography/tandem mass spectrometry; LSC, liquid scintillation counting; IS, internal standard; GI, gastrointestinal.

  • ↵1 Current affiliation: Department of Drug Metabolism, Merck and Co., Inc., West Point, PA.

  • ↵2 Current affiliation: Genentech, South San Francisco, CA.

    • Received August 12, 2007.
    • Accepted April 16, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 36 (7)
Drug Metabolism and Disposition
Vol. 36, Issue 7
1 Jul 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Metabolism and Disposition of Dasatinib after Oral Administration to Humans
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
Citation Tools
Research ArticleArticle

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

Lisa J. Christopher, Donghui Cui, Chiyuan Wu, Roger Luo, James A. Manning, Samuel J. Bonacorsi, Michael Lago, Alban Allentoff, Francis Y. F. Lee, Betty McCann, Susan Galbraith, Donald P. Reitberg, Kan He, Anthony Barros, Anne Blackwood-Chirchir, W. Griffith Humphreys and Ramaswamy A. Iyer
Drug Metabolism and Disposition July 1, 2008, 36 (7) 1357-1364; DOI: https://doi.org/10.1124/dmd.107.018267

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

Lisa J. Christopher, Donghui Cui, Chiyuan Wu, Roger Luo, James A. Manning, Samuel J. Bonacorsi, Michael Lago, Alban Allentoff, Francis Y. F. Lee, Betty McCann, Susan Galbraith, Donald P. Reitberg, Kan He, Anthony Barros, Anne Blackwood-Chirchir, W. Griffith Humphreys and Ramaswamy A. Iyer
Drug Metabolism and Disposition July 1, 2008, 36 (7) 1357-1364; DOI: https://doi.org/10.1124/dmd.107.018267
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Abundant expression of OCT2, MATE1, OAT1, OAT3, PEPT2, BCRP, MDR1 and xCT transporters in blood-arachnoid barrier of pig, and polarized localizations at CSF- and blood-facing plasma membranes
  • Pharmacokinetics of Organic Cation Transporter 1 (OCT1) Substrates in Oct1/2 Knockout Mice and Species Difference in Hepatic OCT1-mediated Uptake
  • Human Cytochrome P450 1A1 Adapts Active Site for Atypical Nonplanar Substrate
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics